DART partner Optellum has attained CE marking in Europe.
This latest certification will allow for use in the European Union (EU) and the United Kingdom (UK), and opens the door to a European expansion for the growing company. It is the latest milestone for Optellum, which received FDA 510(k) clearance in early 2021 as the first AI-assisted diagnosis application for lung cancer. You can read the full press release online here.
In addition, researchers from the University of Oxford and Oxford University Hospitals NHS Foundation Trust (OUH) have published the results of an academic study in European Radiology which takes a closer look at the Optellum Lung Cancer Prediction (LCP) model. You can read the full story on Optellum’s website here.
Celebrate Doncaster LHC’s success
May 4, 2022
The Doncaster programme has been operational since mid-March 2021 and in the first year 11,857 lung health check calls and more…
Registration with ISRCTN
April 8, 2022
Approvals and adoption
March 2, 2022
GE Healthcare and Optellum join forces to advance Lung Cancer Diagnosis with Artificial Intelligence
November 29, 2021